SuperworthMonte Rosa Therapeutics EPS GLUE
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$1.75
- Latest quarter, Q2 FY26
- −$0.43
- Fiscal year 2025
- −$0.45
Monte Rosa Therapeutics' earnings per share was −$1.75 over the twelve months to Jun 30, 2026, down 703% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.43.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.45 | n/a |
| FY2024 | −$1.09 | n/a |
| FY2023 | −$2.64 | n/a |
| FY2022 | −$2.29 | −187% |
| FY2021 | $2.62 | n/a |
| FY2020 | −$22.92 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.43 | n/a | −$1.75 | |
| Q1 FY26 | −$0.45 | −179% | −$1.47 | |
| Q4 FY25 | −$0.54 | −438% | −$0.45 | |
| Q3 FY25 | −$0.33 | n/a | $0.25 | |
| Q2 FY25 | −$0.15 | n/a | $0.29 | |
| Q1 FY25 | $0.57 | n/a | $0.01 | |
| Q4 FY24 | $0.16 | n/a | −$1.09 | |
| Q3 FY24 | −$0.29 | n/a | −$1.83 | |
| Q2 FY24 | −$0.43 | n/a | −$2.24 | |
| Q1 FY24 | −$0.53 | n/a | −$2.52 | |
| Q4 FY23 | −$0.58 | n/a | −$2.64 | |
| Q3 FY23 | −$0.70 | n/a | −$2.69 |
Against its peers
Companies in Biotechnology nearest Monte Rosa Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| GLUEMonte Rosa Therapeutics | −$1.75 | −703% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| Peer median | $0.70 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Monte Rosa Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.